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Abstract
Objective. To evaluate the association between inflammatory markers and relapse in GCA patients
longitudinally assessed in a clinical trial of infliximab and glucocorticosteroids.
Methods. Forty-four newly diagnosed GCA patients in glucocorticosteroid-induced remission were
randomized to receive infliximab 5mg/kg or placebo plus daily glucocorticosteroids, tapered using a
standardized schedule. Sera were analysed for inflammatory markers at multiple, pre-defined time
points. Temporal artery biopsies were performed in four patients before and after treatment to analyse
changes in inflammatory and vascular remodelling marker expression.
Results. Thirteen of 44 patients relapsed. Similar proportions of relapsed patients were present in both
treatment arms. ESR, CRP, intercellular adhesion molecule (ICAM)-1, TNF-a, and IL-12p40 were signifi-
cantly elevated near relapse. In post-treatment biopsies, mRNA expression of pro-inflammatory cytokines
decreased, while vascular remodelling factors increased relative to baseline biopsies. Tissue IL-12p40 and
IFN-g mRNA remained elevated in relapsing vs remitting patients.
Conclusion. Despite prior findings of high concentrations of TNF-a in temporal artery biopsies of GCA
patients, infliximab plus glucocorticosteroids did not result in improved clinical outcomes. Increased
measures of this biomarker did not provide useful insight into the relative importance of TNF-a in the
pathogenesis of GCA. Gene expression analysis in paired temporal artery biopsies pre- and
post-treatment revealed decreased inflammatory activity and active vascular remodelling following treat-
ment. In relapsing patients, increased expression of IFN-g and IL-12p40 in post-treatment biopsies sug-
gests a role in sustaining disease and setting the stage for relapse during treatment withdrawal.
Trial registration. ClinicalTrials.gov; http://www.clinicaltrials.gov; NCT00076726.
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Introduction
GCA is a granulomatous arteritis characterized by
inflammation of large- and medium-sized arteries.
Vascular inflammatory infiltrates are composed predom-
inantly of macrophages, CD4
+ T lymphocytes and den-
dritic cells [1, 2]. Inflammatory infiltrates express a
variety of pro-inflammatory cytokines (i.e. IL-1b, TNF-a,
IL-6 and IFN-g), chemokines (CCL-2), adhesion molecules
[e.g. E-selectin, intercellular adhesion molecule (ICAM)-1
and vascular cell adhesion molecule (VCAM)-1] and
growth factors (e.g. VEGF, TGF-b, PDGF) that are thought
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Eto contribute to vascular inflammation, injury, or tissue
repair and remodelling (reviewed in [35]). Elevated
serum concentrations of some of these molecules [e.g.
IL-6, TNF-a, soluble intercellular adhesion molecule
(sICAM)-1] can be detected in patients with active GCA
[68]. Increased expression of TNF-a and CCL2 in lesions
at diagnosis has been associated with persistent disease
activity [9, 10].
Although treatment with glucocorticosteroids dramatic-
ally improves GCA symptoms [11, 12], glucocorticosteroid
tapering leads to relapse in 4050% of patients in the
majority of series [11, 13, 14], and up to 8491% in the
context of clinical trials with rapid, pre-defined, glucocor-
ticosteroid tapering [15, 16]. Relapses result in frequent
retreatment and incremental glucocorticosteroid-related
toxicity [11, 13, 14, 17]. In a recent clinical trial, the add-
ition of infliximab to a standardized tapering schedule of
glucocorticosteroids did not reduce relapse rates or cu-
mulative glucocorticosteroid dosing in patients with newly
diagnosed GCA [18]. In this study, we evaluated tissue
and serum concentrations of IL-1b, TNF-a, IL-6, IFN-g,
IL-12, PDGF, MMP-9, ICAM-1 and TGF-b, each of which
has been considered to play a role in GCA [310, 1926].
We analysed the relationship of serum biomarker expres-
sion to GCA disease activity and expression of inflamma-
tory and vascular remodelling factors in paired temporal
artery biopsies before and after 1 year of treatment.
Patients and methods
Patients and study design
The study design and clinical trial results have been pre-
viously described [18]. Briefly, 44 patients with newly diag-
nosed GCA in glucocorticosteroid-induced remission
were randomly assigned to receive infliximab 5mg/kg
(n=28) or placebo (n=16) at Weeks 0, 2, 6 and every
8 weeks thereafter. Glucocorticosteroid dosing was
tapered according to a pre-defined schedule. A consen-
sus definition of relapse was created by the steering com-
mittee and investigators participating in this trial. GCA
relapse was defined as an increase in ESR from normal
to 540mm in the first hour, plus one protocol-specified
symptom or sign of GCA [18]. The study was approved
by the institutional review boards or ethics committees
of the individual study sites. The study was conducted
according to the current regulations of the US Food
and Drug Administration, the International Conference
on Harmonization guidelines, and the principles of the
Declaration of Helsinki. All patients provided written in-
formed consent before participating in any protocol-
specific procedures. An independent safety monitoring
committee reviewed safety information during the trial.
Biomarker selection
Biomarkers were selected by consensus by the investiga-
tors during the design of the clinical trial [18]. Selection
was based on previously known expression in GCA le-
sions and association with disease phenotype [3, 9, 19,
2326], histopathological characteristics [21, 22] or
disease outcome [9, 10]. These included Th1-related cyto-
kines (IL-12 and IFN-g), pro-inflammatory cytokines (IL-1b,
TNF-a, IL-6), adhesion molecules (ICAM-1), metalloprotei-
nases (MMP-9) and vascular remodelling factors (TGF-b1,
PDGF A and B). All these factors were investigated in
tissue samples. With the exceptions of IL-1b and IFN-g,
which are barely detectable in human serum, other bio-
marker concentrations were also measured in patient’s
sera.
Serum biomarker assessments
Serum samples were collected at pre-defined time points
during the trial (Weeks 0, 2, 6, 14, 22 and 30) and tested
for TNF-a, IL-6, IL-12p40, PDGF, MMP-9, ICAM-1 and
TGF-b concentrations (R&D Systems; Minneapolis,
MN, USA). CRP concentrations were evaluated every
4 weeks using the Tina-quant kit (Roche; Indianapolis,
IN, USA). ESR was measured in local laboratories.
Temporal artery biopsies
Four patients in whom temporal artery biopsies were ob-
tained at the time of diagnosis before starting glucocorti-
costeroid treatment agreed to have second biopsies
performed on the contra-lateral side after 4652 weeks
of treatment. One patient received placebo and three
received infliximab in addition to glucocorticosteroids.
After surgical removal, half of each of the four paired biop-
sies was embedded in RNAlater Ice and snap-frozen in
liquid nitrogen. The rest of the specimen was embedded
in optimum cutting temperature (OCT) compound and
frozen in methylbutane pre-chilled in liquid nitrogen.
Cryostat sections were haematoxylineosin stained for
histopathological diagnosis and the remaining tissue
was stored at 80C until use for immunohistochemical
studies.
RNA isolation and cDNA synthesis
Temporal artery biopsy samples were homogenized in
TRIzol Reagent (Invitrogen; Carlsbad, CA, USA) and
RNA was extracted according to manufacturer’s instruc-
tions. Total RNA (1mg) was reverse transcribed to cDNA
using the Archive kit (Applied Biosystems; Foster City, CA,
USA) in a final volume of 100ml, using random hexamers
as a priming method. Reaction conditions were adjusted
to the recommendations of the manufacturer. Samples
were stored at 20C until use.
Real-time quantitative PCR
cDNA was quantified by real-time PCR using specific
Pre-Developed TaqMan gene expression assays
(Applied Biosystems). Fluorescence was detected with
ABI PRISM 7900 Sequence Detection system and ana-
lysed with Sequence Detection Software v.2.3 (Applied
Biosystems). All samples were normalized to the expres-
sion of endogenous control GUSb. The comparative CT
method was used to assess relative gene expression.
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To search for additional molecules associated with dis-
ease recurrence, 90 genes were explored in post-
treatment biopsies using the TaqMan Human Immune
gene signature array, a quantitative real-time PCR-based
system (Applied Biosystems). This gene expression card
includes 4 transcription factors, 10 signal transducer mol-
ecules, 32 cytokines/cytokine receptors, 11 chemokines/
chemokine receptors, 5 cell cycle protein kinases, 17 cell
surface receptors, 4 molecules related to stress response,
3 oxidoreductase products and 6 housekeeping genes
to normalize results (www.appliedbiosystems.com)
(see supplementary table 1, available as supplementary
data at Rheumatology Online). Values obtained from a
normal temporal artery biopsy from a patient not diag-
nosed with GCA were used as a standard reference for
comparison of multiple genes (Applied Biosystems
Sequence Detection Systems version 2.3). Based on the
results obtained, two additional genes (IL-23p19 and
IL-17), not included in the expression card, were explored
in all biopsy samples by real-time PCR. IL-23p19 was also
evaluated by immunohistochemistry.
Immunohistochemistry
Among the markers detected by real-time PCR, IL-1b,
TNF-a, IL-6, IFN-g, IL-12p40, IL-12p35, IL-23p19,
MMP-9 and TGF-b were also assessed by immunohisto-
chemistry in pre- and post-treatment biopsies. Limited
availability of OCT-embedded tissue prevented the exten-
sion of the study to additional markers. Cryostat (46mm)
sections were air-dried, fixed in cold acetone and permea-
bilized with 0.1% saponin. Endogenous peroxidase was
blocked with H2O2 and the slides were incubated with the
primary antibodies listed in Table 1. Optimal dilutions were
tested on frozen sections of surgically excised human
tonsils (positive control). Immunoglobulins obtained
from the same species served as negative controls.
Immunodetection was performed with an HRP-labelled
polymer conjugated to secondary antibodies (EnVision
Visualization method, Dako, Glostrup, Denmark) using
diaminobenzidine as a chromogen. Slides were counter-
stained with haematoxylin. Immunostaining was scored
by two investigators (J.H.-R. and M.C.C.) blinded to clin-
ical data, as previously described [8, 10, 19]. Full agree-
ment was achieved in the scores of 96% of the slides
evaluated. After discussion, consensus was achieved for
the remaining determinations.
Statistical analysis
Median serum marker concentrations were determined at
Weeks 0, 2, 6, 14, 22 and 30. For patients who relapsed,
summary statistics were provided for each serum marker
over time and paired median marker concentrations
were compared between baseline and time of relapse.
Group-wise comparisons were made using analysis of
variance on the van der Waerden scores. P-values un-
adjusted for multiplicity were calculated for exploratory
analysis. Paired t-test (InStat program) was used for com-
parison of mRNA biomarker data between the first and
second biopsies.
Results
Serum biomarker concentrations in relapsing vs
remitting patients
At baseline (Week 0), all patients were in glucocorticoster-
oid-induced remission. Thirteen of 44 patients had
protocol-specified relapses [18] during glucocorticoster-
oid tapering; four were receiving placebo and nine were
receiving infliximab. Overall, higher ESR and median
serum concentrations of TNF-a, IL-6, IL-12p40, TGF-b,
MMP-9, ICAM-1, PDGF and CRP were observed in relap-
sing patients vs those who achieved sustained remission
(Table 2). Differences were statistically significant for ESR,
CRP, ICAM-1 and PDGF at particular time points dur-
ing follow-up, especially at Week 2 after the study entry
(Table 2). IL-1b and IFN-g could not be measured because
their concentrations were below or near the detection
threshold.
In patients who relapsed, significantly (P<0.01) ele-
vated median values were observed at the protocol-
specified visit closest to relapse vs baseline for ESR
(77 vs 20mm/h), CRP (1.90 vs 0.5mg/dl), ICAM-1
(298.33 vs 235.70ng/ml), TNF-a (10.95 vs 2.45pg/ml)
and IL-12p40 (60.06 vs 7.80pg/ml).
Changes in serum markers according to treatment
Despite no observed differences between groups with
regard to clinical outcomes, median concentrations of
TNF-a, IL-12p40, ICAM-1 and CRP were significantly
TABLE 1 Antibodies used for immunohistochemistry
Target molecule Species Type Source Dilution
IL-1b Mouse Monoclonal (clone B1) Genzyme 1:50
IL-6 Mouse Monoclonal (clone 6708) R&D Systems 1:40
TNF-a Mouse Monoclonal (clone 1825) R&D Systems 1:40
IFN-g Mouse Monoclonal (clone 25718.11) R&D Systems 1:100
TGF-b Rabbit Polyclonal R&D Systems 1:100
MMP-9 Mouse Monoclonal (clone GE-213) Chemicon 1:100
IL-12p40 Mouse Monoclonal (clone I-1A4) AbD Serotec 1:1000
IL-12p35 Rabbit Polyclonal ATLAS Antibodies 1:1000
IL-23p19 Rabbit Polyclonal Abcam 1:1500
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Markers of inflammation in GCAdifferent (P<0.05) for patients receiving glucocorticoster-
oids plus infliximab vs those receiving glucocorticoster-
oids plus placebo at select time points post-treatment.
Significantly higher median TNF-a concentrations were
observed in patients receiving infliximab (12.1719.12pg/
ml) vs placebo (2.602.92pg/ml) across all time points.
IL-12p40 concentrations were significantly higher at
Weeks 6 and 14 in patients receiving glucocorticosteroids
plus infliximab (56.58 and 72.06pg/ml, respectively) vs
glucocorticosteroids plus placebo (27.30 and 47.00pg/
ml, respectively). No differences in other markers were
found between patients in each treatment arm.
mRNA expression in paired pre- and post-treatment
temporal artery biopsies
The four patients with second biopsies had different
clinical outcomes. Two of the four patients who experi-
enced three and four relapses continued receiving glu-
cocorticosteroids at 12.5 and 15mg/day, and had
received cumulative glucocorticosteroid doses of 6347
and 8247mg, respectively. The other two patients were
in remission; at second biopsy one had not relapsed
and the other had experienced one relapse. They
were receiving 0 and 8mg prednisone/day, and had
received cumulative prednisone doses of 4285 and
4987mg, respectively.
With the exception of TNF-a, pro-inflammatory cytokine
mRNA expression decreased post-treatment with gluco-
corticosteroid plus infliximab or placebo (Table 3). T-cell
co-stimulatory and adhesion molecule ICAM-1 expression
also decreased. Among Th1 cytokines, IFN-g expression
decreased whereas IL-12p40 tended to increase post-
treatment.
A survey of 90 genes expressed in second biopsies re-
vealed that patients with more frequent relapses had
higher concentrations of IL-12p40 and IFN-g mRNA in
their post-treatment biopsies than patients who were
more responsive to treatment (Fig. 1). IL-12p40 mRNA
remained elevated in frequent relapsing patients but was
undetectable in patients in remission. IL-12p35 mRNA
was present in low concentrations in frequently relapsing
patients. These levels suggested that persistence of
IL-12p40 might be partly related to IL-23 (the IL-23p19
subunit is shared with the IL-12p40 subunit), which was
not included in the gene-expression card. IL-23p19 mRNA
and its related cytokine IL-17 were subsequently analysed
by real-time PCR and found to be over-expressed in
pre-treatment biopsies and decreased with treatment
(Table 3). Although other mRNAs were elevated, no
TABLE 2 Median serum biomarker concentrations in patients who relapsed and non-relapsing patients over different
time points
Biomarker Week 0
a Week 2 Week 6 Week 14 Week 22
ESR, mm/h
Relapse 20.00 47.50* 58.00* 67.00* 54.50
No relapse 10.00 10.00 23.00 23.00 31.00
CRP, mg/dl
Relapse 0.50 2.05* 0.90 0.85 1.80
No relapse 0.40 0.40 0.65 0.60 1.00
TNF-a, pg/ml
Relapse 2.45 4.90 12.85 12.17 10.18
No relapse 2.47 8.73 9.85 8.16 16.09
IL-6, pg/ml
Relapse 6.57 16.76 3.27 8.05 17.46
No relapse 2.75 3.80 3.28 5.59 5.92
IL-12p40, pg/ml
Relapse 7.80 32.16 57.85 105.35 189.78
No relapse 7.80 18.57 38.85 61.81 101.12
PDGF, pg/ml
Relapse 22261.44 34160.05* 21564.19 17640.36 22216.81
No relapse 18201.11 19761.95 21323.37 21574.78 23713.13
MMP-9, ng/ml
Relapse 1117.46 1957.49 1297.05 642.18 1138.22
No relapse 1585.64 1217.77 1329.28 931.03 1070.42
ICAM-1, ng/ml
Relapse 235.70 436.71* 415.10 271.12 372.27*
No relapse 231.99 227.64 315.57 270.13 279.21
TGF-b, pg/ml
Relapse 41.60 45.41 45.59 42.30 36.88
No relapse 38.72 38.29 38.39 39.61 38.62
aAt week 0 all patients were in glucocorticoid-induced remission. *P<0.05 for comparison between relapsed and non-
relapsing patients.
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relapsing and remitting patients.
Immunohistochemical expression in paired temporal
artery biopsies obtained pre- and post-treatment
A substantial reduction in the intensity of inflammatory
infiltrates was observed in biopsies collected post-
treatment with glucocorticosteroids plus infliximab or pla-
cebo compared with those obtained at the time of diag-
nosis. Only scattered foci of inflammatory cells persisted
in second biopsies. Immunohistochemical scores for all of
the markers tested were reduced in proportion to the de-
crease in inflammatory cells (Fig. 2). Figure 3 shows the
topographic distribution of the products associated with
relapse in pre- and post-treatment biopsies. As with other
markers, IFN-g, IL-12p35, IL-23p19 and IL-12p40 immu-
nohistochemical expression decreased. Intense expres-
sion of these markers was observed in a cluster of
infiltrating cells located in the adventitia in post-treatment
biopsies. Smooth muscle cells immunostained slightly
FIG.1mRNA concentrations (Th1 cytokines) in post-treatment temporal artery biopsies from patients who relapsed and
those who did not relapse. Values are relative to those found in a normal temporal artery. In addition to glucco-
corticosteroids, Patient 1 received placebo and Patients 24 received infliximab.
TABLE 3 Changes in biomarker mRNA concentration
[mean (SEM)] in paired temporal artery biopsies
a
Biomarker First biopsy Second biopsy P-value
IL-1b 63.19 (19.76) 17.23 (5.34) 0.144
TNF-a 10.18 (2.39) 19.94 (4.65) 0.246
IL-6 353.88 (90.72) 32.81 (18.46) 0.058
IFN-g 232.62 (78.95) 16.80 (5.48) 0.064
IL-12p40 0.20 (0.20) 1.99 (0.71) 0.066
IL-12p35 7.22 (2.99) 13.34 (1.33) 0.051
IL-23p19 13.00 (6.47) 5.06 (1.94) 0.198
IL-17 2.57 (1.07) 0.35 (0.15) 0.250
ICAM-1 471.11 (67.82) 159.30 (24.94) 0.032
MMP-9 188.22 (46.22) 356.14 (124.78) 0.253
TGF-b 1080.78 (208.46) 1819.12 (55.16) 0.050
PDGF-A 598.58 (328.13) 1262.48 (311.36) 0.009
PDGF-B 354.17 (177.39) 532.76 (101.99) 0.253
aNumber of paired biopsies=4. Statistics are only indicative
given the low number of samples studied.
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Markers of inflammation in GCApositive for IL-12p35 (Fig. 3), reflecting the constitutive
expression of this IL-12 subunit in normal arteries (Fig. 1).
Discussion
This is the first prospectively designed study of GCA [18]
to examine biomarkers and a large number of genes and
proteins in paired sets of pre-treatment vs post-treatment
biopsies [27, 28]. Patients with relapsing GCA had higher
overall concentrations of acute-phase reactants, adhesion
molecules and inflammatory cytokines than patients who
did not relapse. Significantly increased values of CRP,
ESR, ICAM-1, TNF-a and IL-12p40 were observed at re-
lapse relative to baseline.
This study confirmed previously published data show-
ing associations between elevated tissue TNF-a concen-
trations and active disease [8, 9, 29]. Nonetheless, our trial
evaluating the addition of infliximab to glucocorticoster-
oids did not result in improved clinical outcomes [17]. In
the context of GCA and TNF, we conclude that increased
measures of this biomarker did not provide useful insight
into just how critical TNF is in GCA. Attempting to achieve
therapeutic benefit by blocking TNF was unsuccessful.
One could argue that the dose and treatment schedule
employed was insufficient to see an effect. However, the
lack of any clinical signal of benefit, with doses that are
usually effective in other diseases, makes this unlikely. It is
more likely that our results reflect an incomplete under-
standing of cytokine-cell cross-talk and immunoregulation
in GCA.
We did find a sharp increase in median serum concen-
trations of other select inflammatory and vascular remo-
delling markers at Week 2 after enrolment showing a clear
difference in marker levels between patients who would
experience a subsequent relapse and patients who did
not relapse. Differences were statistically significant
for CRP, ESR, ICAM-1 and PDGF. Trends were observed
for IL-6, IL-12p40 and PDGF, although these did not reach
a level of statistical significance. This rebound effect coin-
cided with the beginning of glucocorticosteroid tapering,
suggesting that relapsing patients may be identified early
during the course of the disease and that monitoring early
changes in select serum markers may be warranted after
treatment initiation. Unfortunately, none of the molecules
showed consistent or dramatic differences between relap-
sing and remitting patients across all the time points
tested. Patients treated with infliximab had paradoxically
higher serum concentrations of TNF-a and IL-12p40. While
FIG.2Immunohistochemical expression scores for the cytokines studied in pre- and post-treatment temporal artery
biopsies.
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it may result from interference with negative feed-back
loops, as observed in other settings [30, 31].
In paired biopsies obtained from four patients with
GCA, mRNA concentrations of select inflammatory mark-
ers (IL-1b, IL-6, IFN-g, ICAM-1) decreased and concentra-
tions of factors participating in vascular remodelling
(MMP-9, TGF-b, PDGF-A and PDGF-B) were increased
after 1 year of treatment, suggesting progression towards
tissue repair.
Immunohistochemical scores for inflammatory markers
decreased post-treatment and correlated with the reduc-
tion in inflammatory cells in biopsies.
Simultaneous screening for 90 genes revealed elevated
mRNA concentrations of IFN-g and IL-12p40 in the
second biopsies of two patients with multiple relapses.
FIG.3Distribution of IL-12p40, IL-12p35, IL-23p19 and IFN-g expression in pre- and post-treatment temporal artery
biopsies from two relapsing patients. The first three rows correspond to one patient and the fourth row to the other.
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Markers of inflammation in GCAGiven that the IL-12p70 heterodimer (p40/p35) is a
stimulator of Th1 differentiation and IFN-g production,
our results support a relationship between Th1-mediated
response and relapsing disease. However, the IL-12p35
subunit of IL-12 was decreased in the second biopsies of
relapsing patients, suggesting that increased IL-12p40
could also be part of the IL-23 (p40/p19) heterodimer.
Indeed, IL-23p19 and its related cytokine IL-17A were
up-regulated in our patients, as recently reported in
larger series of active patients [3234]. Immunostaining
of post-treatment biopsies disclosed clusters of cells ex-
pressing these cytokines in the adventitia, where arterial
inflammation is initiated in GCA [22, 35, 36].
Our study has several important limitations. The time
points of serum sampling were pre-defined and thus
were not precisely coincident with the occurrence of
relapse. The small number of arterial samples analysed
prevents rigorous assessment of the effects of gluco-
corticoids plus infliximab vs placebo on tissue expression
of biomarkers. In addition, second biopsies may not have
completely reflected treatment-induced changes in the
first biopsy. The incomplete reflection of changes is an
inherent limitation to any study performed on serial
biopsies obtained before and after intervention.
Nonetheless, our results suggest that both IFN-g and
IL-23 may be related to disease persistence. This hy-
pothesis on the relationship of IFN-g and IL-23 to dis-
ease persistence is consistent with experimental models
showing that IL-12p40 knockout mice are resistant to
developing various chronic inflammatory diseases and
that IL-12p35 knockout mice develop more severe dis-
ease phenotypes [37, 38]. Further studies are needed to
explore the relative functional contribution of IL-12/
IL-23p40 and IFN-g to disease persistence and the po-
tential to exploit them as therapeutic targets in GCA.
Rheumatology key messages
. Patients with relapsing GCA have moderately ele-
vated acute-phase reactants and other inflamma-
tory molecules.
. Serial temporal artery biopsies reveal decreased
pro-inflammatory cytokines and increased expres-
sion of vascular remodelling factors.
. Persistent tissue expression of IFN-g and IL-12p40
in relapsing patients suggests involvement in dis-
ease chronicity.
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